Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Capromorelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR known ✓ | Q92847 | 18/20 | 0.94 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Capromorelin SCHEMBL5253173 | 1.00 | GHSR (0.94) | GHSRTACR1 | |
| Capromorelin SCHEMBL5246732 | 0.97 | GHSR (1.00) | GHSR | |
| Capromorelin SCHEMBL1147592 | 0.97 | GHSR (1.00) | GHSR | |
| Capromorelin SCHEMBL3245235 | 0.97 | GHSR (1.00) | GHSR | |
| Capromorelin SCHEMBL14977966 | 0.97 | GHSR (1.00) | GHSR | |
| Capromorelin SCHEMBL18804380 | 0.97 | GHSR (1.00) | GHSR | |
| Capromorelin SCHEMBL5245758 | 0.96 | GHSR (0.98) | GHSR | |
| Capromorelin SCHEMBL5245765 | 0.96 | GHSR (0.98) | GHSR | |
| Capromorelin SCHEMBL5245768 | 0.96 | GHSR (0.98) | GHSR | |
| Capromorelin SCHEMBL6738011 | 0.93 | GHSR (0.93) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0869968-B1 | GROWTH-HORMONE SECRETAGOGUES | PFIZER (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1000085-B1 | TREATMENT OF INSULIN RESISTANCE WITH GROWTH HORMONE SECRETAGOGUES | PFIZER PROD INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-6657063-B1 | (4-(2-(2-(6-aminopyridin-3-yl)-2(R)-hydroxyethylamino) ethoxy)phenyl)acetic acid derivatives; dietetics; hypotensive agents; non-insulin dependent diabetes treatment | PFIZER INC. | 2003-12-02 | — | — | US | disclosed |
| US-6630487-B2 | Treatment of insulin resistance with growth hormone secretagogues | PFIZER INC. | 2003-10-07 | — | — | US | disclosed |
| US-20030100561-A1 | Administering 2-amino-N-(1-(3a-benzyl-2-methyl-3-oxo-2,3,3a, 4,6,7-hexahydro-pyrazolo(4,3-c)pyridine-5-carbonyl)-4-phenyl-butyl) -isobutyramide for treating congestive heart failure, obesity | CARPINO PHILIP ALBERT (US) | 2003-05-29 | — | — | US | disclosed |
| US-6482825-B2 | HEXAHYDRO-PYRAZOLO-(4,3-C)PYRIDINE DERIVATIVES USEFUL FOR INCREASING THE ENDOGENOUS PRODUCTION OR RELEASE OF GROWTH HORMONE IN A HUMAN OR OTHER ANIMAL, THUS TREAT OR PREVENT OSTEOPOROSIS | PFIZER INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020049196-A1 | Growth-hormone secretagogues | RAQUALIA PHARMA INC. (JP) | 2002-04-25 | — | — | US | disclosed |
| US-6306875-B1 | ADMINISTERING GROWTH HORMONES DIPEPTIDE COMPOUNDS WHICH ARE GROWTH HORMONE SECRETAGOGUES AND ARE USEFUL FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS. | PFIZER INC. | 2001-10-23 | — | — | US | disclosed |
| US-6278000-B1 | INCREASE LEVEL OF ENDOGENOUS GROWTH HORMONE; USEFUL IN THERAPY AND PROPHYLAXIS OF OSTEOPOROSIS, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING AND OBESITY, ACCELERATING BONE FRACTURE REPAIR | PFIZER INC. | 2001-08-21 | — | — | US | disclosed |
| US-6124264-A | GROWTH HORMONE SECRETAGOGUE IN A HUMAN OR OTHER ANIMAL TO TREAT OSTEOPOROSIS, CONGESTIVE HEART FAILURE, AGING, OBESITY; BONE AND WOUND HEALING AGENTS | PFIZER INC. (US) | 2000-09-26 | — | — | US | disclosed |
| US-6107306-A | OSTEOPOROSIS | PFIZER INC. (US) | 2000-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100561-A1 | Administering 2-amino-N-(1-(3a-benzyl-2-methyl-3-oxo-2,3,3a, 4,6,7-hexahydro-pyrazolo(4,3-c)pyridine-5-carbonyl)-4-phenyl-butyl) -isobutyramide for treating congestive heart failure, obesity | GIPR, GHSR, GPR119 | GHSR 2/4885TACR1 308/4885 |
| US-20020049196-A1 | Growth-hormone secretagogues | GHSR, GHRHR, IGFBP6 | GHSR 1/4885TACR1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.